[1]World Health Organization. Global Tuberculosis Report 2012. Geneva:World Health Organization, 2012.[2]World Health Organization. The global plan to stop TB 2011—2015: transforming the fight towards elimination of tuberculosis. Geneva: World Health Organization, 2010: 1-100.[3]Knight M, Kurinczuk JJ, Nelson-Piercy C, et al. Tuberculosis in pregnancy in the UK. BJOG, 2009, 116(4): 584-588.[4]Cheung JY, Shim SS, Kim Y. Infectious respiratory diseases in pregnancy-results of a 15-year study in Seoul. Clin Exp Obstet Gynecol, 2011, 38(4): 351-354.[5]张杏怡.妊娠合并结核病的化学治疗.医药导报, 2000, 19(1): 17.[6]王黎霞.中国耐多药结核病的控制亟待加强.中华结核和呼吸杂志, 2009,32(8): 561-563.[7]戴钟英.妊娠期用药FDA五级分类法.中国实用妇科与产科杂志,2004,20(6):377-378.[8]World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva:World Health Organization, 2011.[9]Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med, 2003, 167(4): 603-662.[10]Francis J. Curry National Tuberculosis Center and California Department of Public Health. Drug-resistant tuberculosis:a survival guide for clinicians. 2nd. California: Francis J. Curry National Tuberculosis Center and California Department of Public Health,2011:108-109.[11]Shin S, Guerra D, Rich M, et al. Treatment of multidrug-resistant tuberculosis during pregnancy: a report of 7 cases. Clin Infect Dis, 2003, 36(8): 996-1003.[12]Lessnau KD, Qarah S. Multidrug-resistant tuberculosis in pregnancy: case report and review of the literature. Chest, 2003, 123(3): 953-956.[13]Drobac PC, del Castillo H, Sweetland A, et al. Treatment of multidrug-resistant tuberculosis during pregnancy: long-term follow-up of 6 children with intrauterine exposure to second-line agents. Clin Infect Dis, 2005, 40(11): 1689-1692.[14]Palacios E, Dallman R, Munoz M, et al. Drug-resistant tuberculosis and pregnancy: treatment outcomes of 38 cases in Lima, Peru. Clin Infect Dis, 2009, 48(10): 1413-1419.[15]World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis energency update 2008. Geneva:World Health Organization, 2008.[16]Loebstein R,Addis A,Ho E,et al.Pregnancy outcome following gestational exposure to fluoroquinolones:a multicenter prospective controlled study. Antimicrob Agents Chemother, 1998,42(6):1336-1339.[17]Potworowski M, Sianozecka E, Szufladowicz R. Ethionamide treatment and pregnancy.Pol Med J,1966,5(5):1152-1158.[18]Nitta AT, Milligan D. Management of four pregnant women with multidrug-resistant tuberculosis. Clin Infect Dis, 1999, 28(6): 1298-1304.[19]Rodríguez G, Pinto R, López F, et al. Persistent type 2 lepra reaction (erythema nodosum) and clofazimine-induced lethal enteropathy. Biomedica, 2009, 29(1): 18-24.[20]Ryo E, Ikeya M, Sugimoto M. Clinical study of the effectiveness of imipenem/cilastatin sodium as the antibiotics of first choice in the expectant management of patients with preterm premature rupture of membranes. J Infect Chemother, 2005, 11(1): 32-36.[21]Einarson A, Phillips E, Mawji F, et al. A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol, 1998, 15(9): 523-525.[22]Drinkard CR, Shatin D, Clouse J. Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations. Pharmacoepidemiol Drug Saf, 2000, 9(7): 549-556.[23]Marcus JC.Non-teratogenicity of antituberculous drugs. S Afr Med J,1967, 41(30):758-759.[24]韩丹,陈志飞,刘妍丽,等.抗结核治疗对中晚期妊娠结核病患者的婴幼儿生长发育影响.中国防痨杂志,2013,35(5):371-374.[25]Brost BC, Newman RB. The maternal and fetal effects of tuberculosis therapy. Obstet Gynecol Clin North Am, 1997,24(3):659-673.[26]马玙,朱莉贞,潘毓萱.结核病.北京:人民卫生出版社,2006:90-91.[27]Lewit T, Nebel L, Terracina S, et al. Ethambutol in pregnancy: observations on embryogenesis. Chest, 1974,66(1):25-26.[28]Snider DE Jr, Layde PM, Johnson MW, et al. Treatment of tuberculosis during pregnancy. Am Rev Respir Dis,1980,122(1):65-79.[29]Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet, 2012, 380(9846):986-993.[30]Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med, 2009, 360(23): 2397-2405.[31]Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med, 2012, 366(23): 2151-2160.[32]Nesri Padayatchi. Linezolid pharmacokinetics(PK) in multi-Drug resistant (MDR)/extensively-drug resistant (XDR) tuberculosis (TB) (S30PK) [R/OL]. Pietermaritzburg:MBChB University of KwaZulu,2012(2012-08-15)[2013-06-09].http://www.who.int/tb/challenges/mdr/programmatic_guidelines_for_mdrtb/en/index.html.[33]Mercieri M, Di Rosa R, Pantosti A, et al. Critical pneumonia complicating early-stage pregnancy. Anesth Analg, 2010, 110(3): 852-854.[34]中国防痨协会临床专业委员会.孕妇应用抗结核药物的注意事项(试行). 中国防痨杂志,1993,15(2):82.[35]Gach O, Corhay JL, Lousberg L, et al. Breast abscess and pregnancy toxemia revealing multidrug resistant tuberculosis. Rev Mal Respir, 1999, 16(5): 842-845.[36]中国全球基金结核病项目办公室. 中国全球基金结核病项目(一期)实施细则. 北京:中国全球基金结核病项目办公室,2012:45.[37]Takashima T, Danno K, Tamura Y, et al. Treatment outcome of patients with multidrug-resistant pulmonary tuberculosis during pregnancy. Kekkaku, 2006, 81(6): 413-418.[38]Tabarsi P, Baghaei P, Mirsaeidi M, et al. Multi-drug resistant tuberculosis in pregnancy: need for more intensive treatment. Infection, 2007, 35(6): 477-478.[39]Tabarsi P, Moradi A, Baghaei P, et al. Standardised second-line treatment of multidrug-resistant tuberculosis during pregnancy. Int J Tuberc Lung Dis, 2011, 15(4): 547-550. |